Cargando…
The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority?
INTRODUCTION: Diagnosis, treatment monitoring and assessment of desmopressin effect in haemophilia A patients are performed by measurement of factor VIII activity (FVIII). The two assays commonly applied are the one‐stage assay and the chromogenic assay. Especially in non‐severe haemophilia A, discr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590113/ https://www.ncbi.nlm.nih.gov/pubmed/32713129 http://dx.doi.org/10.1111/hae.14106 |
_version_ | 1783600733055090688 |
---|---|
author | Schütte, Lisette M. Hodes, Luca S. van Moort, Iris Stoof, Sara C. M. Leebeek, Frank W. G. Cnossen, Marjon H. de Maat, Moniek P. M. Kruip, Marieke J. H. A. |
author_facet | Schütte, Lisette M. Hodes, Luca S. van Moort, Iris Stoof, Sara C. M. Leebeek, Frank W. G. Cnossen, Marjon H. de Maat, Moniek P. M. Kruip, Marieke J. H. A. |
author_sort | Schütte, Lisette M. |
collection | PubMed |
description | INTRODUCTION: Diagnosis, treatment monitoring and assessment of desmopressin effect in haemophilia A patients are performed by measurement of factor VIII activity (FVIII). The two assays commonly applied are the one‐stage assay and the chromogenic assay. Especially in non‐severe haemophilia A, discrepancies between these assays are common. It is still unestablished which assay corresponds best with bleeding phenotype and desmopressin effect. AIM: To correlate FVIII levels measured by the one‐stage assay and by the chromogenic assay with bleeding phenotype and, additionally, to compare FVIII assay discrepancies before and after desmopressin administration. METHOD: Factor VIII was measured in 130 non‐severe haemophilia A patients during routine visits to the outpatient clinic and/or during desmopressin testing. FVIII was measured by both the one‐stage assay and the chromogenic assay. Discrepancies between assays were defined as at least a twofold difference of FVIII or an absolute FVIII difference between measurements of ≥0.10 IU/mL. Bleeding phenotype was defined as annual number of treated bleedings (adjusted ABR). RESULTS: Hundred and thirty non‐severe haemophilia A patients were included. In 31/130 patients, assay results were discrepant. However, FVIII measurements with both assays correlated adequately with adjusted ABR. In addition, in 27/130 patients FVIII measurements at baseline and after desmopressin administration were analysed. In 13/27 patients, all measurements were either equivalent or discrepant when results were compared. In 14/27 patients, this was not the case as both equivalent measurements and discrepant measurements at different time points within one patient were observed. CONCLUSION: Neither the one‐stage assay nor the chromogenic assay is superior in predicting bleeding phenotype. In addition, equivalent or discrepant FVIII results measured before desmopressin do not always predict FVIII assay results after desmopressin administration. |
format | Online Article Text |
id | pubmed-7590113 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75901132020-10-30 The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority? Schütte, Lisette M. Hodes, Luca S. van Moort, Iris Stoof, Sara C. M. Leebeek, Frank W. G. Cnossen, Marjon H. de Maat, Moniek P. M. Kruip, Marieke J. H. A. Haemophilia Original Articles INTRODUCTION: Diagnosis, treatment monitoring and assessment of desmopressin effect in haemophilia A patients are performed by measurement of factor VIII activity (FVIII). The two assays commonly applied are the one‐stage assay and the chromogenic assay. Especially in non‐severe haemophilia A, discrepancies between these assays are common. It is still unestablished which assay corresponds best with bleeding phenotype and desmopressin effect. AIM: To correlate FVIII levels measured by the one‐stage assay and by the chromogenic assay with bleeding phenotype and, additionally, to compare FVIII assay discrepancies before and after desmopressin administration. METHOD: Factor VIII was measured in 130 non‐severe haemophilia A patients during routine visits to the outpatient clinic and/or during desmopressin testing. FVIII was measured by both the one‐stage assay and the chromogenic assay. Discrepancies between assays were defined as at least a twofold difference of FVIII or an absolute FVIII difference between measurements of ≥0.10 IU/mL. Bleeding phenotype was defined as annual number of treated bleedings (adjusted ABR). RESULTS: Hundred and thirty non‐severe haemophilia A patients were included. In 31/130 patients, assay results were discrepant. However, FVIII measurements with both assays correlated adequately with adjusted ABR. In addition, in 27/130 patients FVIII measurements at baseline and after desmopressin administration were analysed. In 13/27 patients, all measurements were either equivalent or discrepant when results were compared. In 14/27 patients, this was not the case as both equivalent measurements and discrepant measurements at different time points within one patient were observed. CONCLUSION: Neither the one‐stage assay nor the chromogenic assay is superior in predicting bleeding phenotype. In addition, equivalent or discrepant FVIII results measured before desmopressin do not always predict FVIII assay results after desmopressin administration. John Wiley and Sons Inc. 2020-07-26 2020-09 /pmc/articles/PMC7590113/ /pubmed/32713129 http://dx.doi.org/10.1111/hae.14106 Text en © 2020 The Authors. Haemophilia published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Schütte, Lisette M. Hodes, Luca S. van Moort, Iris Stoof, Sara C. M. Leebeek, Frank W. G. Cnossen, Marjon H. de Maat, Moniek P. M. Kruip, Marieke J. H. A. The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority? |
title | The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority? |
title_full | The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority? |
title_fullStr | The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority? |
title_full_unstemmed | The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority? |
title_short | The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority? |
title_sort | one‐stage assay or chromogenic assay to monitor baseline factor viii levels and desmopressin effect in non‐severe haemophilia a: superiority or non‐inferiority? |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590113/ https://www.ncbi.nlm.nih.gov/pubmed/32713129 http://dx.doi.org/10.1111/hae.14106 |
work_keys_str_mv | AT schuttelisettem theonestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority AT hodeslucas theonestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority AT vanmoortiris theonestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority AT stoofsaracm theonestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority AT leebeekfrankwg theonestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority AT cnossenmarjonh theonestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority AT demaatmoniekpm theonestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority AT kruipmariekejha theonestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority AT schuttelisettem onestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority AT hodeslucas onestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority AT vanmoortiris onestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority AT stoofsaracm onestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority AT leebeekfrankwg onestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority AT cnossenmarjonh onestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority AT demaatmoniekpm onestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority AT kruipmariekejha onestageassayorchromogenicassaytomonitorbaselinefactorviiilevelsanddesmopressineffectinnonseverehaemophiliaasuperiorityornoninferiority |